2025-08-03 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX), incorporating the provided data.

## RXRX Stock Analysis (Recursion Pharmaceuticals Inc)

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -45.04%
*   **VOO Cumulative Return:** 33.25%
*   **Relative Deviation:**
    *   Max Deviation: 33.2
    *   Min Deviation: -90.5
    *   Current Deviation: -84.1
    *   Relative Deviation Percentile: 5.2

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the observed period. The current deviation is near the lowest end of its historical range relative to VOO. This indicates substantial underperformance compared to the broader market. The relative deviation percentile of 5.2 suggests that RXRX is performing in the bottom percentile of its historical relative performance against VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -1.0% | -0.1 | 4.3 |
| 2022-2024  | 0.0% | 73.6% | -25.0% | 0.1 | 2.9 |
| 2023-2025  | 6.0% | 73.6% | -40.0% | 0.1 | 2.5 |

**Analysis:** The table presents the performance metrics for RXRX over different periods.
*   **CAGR:** Compounded Annual Growth Rate shows moderate growth in the 5-6% range for the observed periods.
*   **MDD:** Maximum Drawdown is consistently high at 73.6%, indicating significant potential for losses.
*   **Alpha:** Alpha is negative across all periods, suggesting underperformance relative to the market.
*   **Beta:** Beta values are low (around 0.1), implying low correlation with the market.
*   **Cap(B):** The market capitalization has decreased from $4.3B to $2.5B over the periods, indicating a decline in the company’s market value.

### 2. Recent Price Action

*   **Current Price:** $5.68
*   **Previous Close:** $5.95
*   **Change:** -4.54%
*   **5-day Moving Average:** $5.94
*   **20-day Moving Average:** $5.81
*   **60-day Moving Average:** $5.11

**Analysis:** The stock experienced a significant drop of -4.54% in the last market session. The price is currently below its 5-day and 20-day moving averages but above the 60-day moving average, suggesting a short-term downward trend but a longer-term potential support level. The recent drop highlights the volatility in the stock.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3358 (Low Risk)
*   **RSI:** 56.71
*   **PPO:** -0.98
*   **Hybrid Signal:** cash_70%_Sell 70.0% of holdings (3431 shares - Caution - MRI:0.34)
*   **Delta Previous Relative Divergence (20-day):** -1.9 (Negative - Short-term decline)
*   **Expected Return (%):** -529.9%

**Analysis:**

*   **MRI:** The MRI indicates low market risk for RXRX.
*   **RSI:** The RSI of 56.71 is neutral, suggesting the stock is neither overbought nor oversold.
*   **PPO:** The PPO is slightly negative (-0.98), indicating a possible short-term downward trend.
*   **Hybrid Signal:** The hybrid signal recommends selling 70% of holdings and increasing the cash ratio to 70%, suggesting a cautious approach.
*   **Delta Previous Relative Divergence:** Indicates recent short-term decline, reinforcing negative sentiment.
*   **Expected Return:**  The significantly negative expected return (-529.9%) suggests that, based on current models, long-term investment in RXRX is projected to significantly underperform the S&P 500.

### 4. Recent News & Significant Events

*   **2025-07-30:** Major business developments, regulatory changes, or market events.
*   **2025-08-03:** Analyst discussions on performance and outlook considering industry trends and global factors.
*   **2025-08-02:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-31:** Market experts highlight risks and opportunities, advising monitoring of recent news and announcements.

**Analysis:** Recent news suggests significant activity and volatility surrounding RXRX, with analysts actively discussing its prospects. Investors should monitor company announcements and news for further developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2024-05-09 | -0.39 | 0.01 B$  |
| 2025-05-05 | -0.39 | 0.01 B$  |

**Analysis:** The earnings data shows consistent negative EPS and relatively low revenue. This indicates the company is currently unprofitable and has limited revenue generation, typical for a growth-stage biotech company focused on R&D.

### 6. Financial Information

Revenue and Profitability:

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-03-31   | $0.01B   | -47.31%       |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |
| 2024-06-30   | $0.01B   | 36.14%        |
| 2024-03-31   | $0.01B   | 17.23%        |

Capital and Profitability:

| Quarter      | Equity   | ROE       |
|--------------|----------|-----------|
| 2025-03-31   | $0.93B   | -21.68%   |
| 2024-12-31   | $1.03B   | -17.29%   |
| 2024-09-30   | $0.52B   | -18.27%   |
| 2024-06-30   | $0.58B   | -16.69%   |
| 2024-03-31   | $0.40B   | -22.78%   |

**Analysis:**
*   **Revenue and Profitability:** Revenue fluctuates, with a significant drop in some quarters. Profit margins are generally negative, indicating the company is spending more than it earns. However, there are quarters with positive profit margins, likely due to specific revenue events or partnerships.
*   **Capital and Profitability:** Equity has seen fluctuations, with a peak followed by a decline. ROE is consistently negative, highlighting the company’s inability to generate profit from its equity.

### 7. Overall Summary

RXRX has significantly underperformed the S&P 500 and shows high volatility. The recent price drop and negative indicators like the Hybrid Signal and negative expected return suggest caution. The company’s financials show consistent losses, and although it is a biotech company in a growth phase, it requires close monitoring. Recent news indicates potential upcoming catalysts or challenges.

**Recommendation:** Based on the provided data, a cautious approach is warranted. Investors should monitor company announcements, news, and financial performance closely before making any investment decisions. The negative expected return and recent downward trends suggest high risk.
